Matthew D. Galsky, MD, on Key Takeaways From 2021 ASCO Annual Meeting in Bladder Cancer

Video

CancerNetwork® sat down with Matthew D. Galsky, MD, at the 2021 ASCO Annual Meeting to discuss his thoughts on research he believes has the greatest potential to impact standard of care treatment of bladder cancer.

At the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, CancerNetwork® spoke with Matthew D. Galsky, MD, of Mount Sinai Hospital in New York, regarding bladder-sparing approaches to bladder cancer and how new data may motivate more clinicians to utilize these treatment strategies. Galsky and colleagues presented findings from a study combining bladder-sparing surgery and systemic neoadjuvant therapy with nivolumab and chemotherapy.

Transcript:

I think that the biggest impact from studies at ASCO this year in the bladder cancer field probably have to do with bladder-sparing approaches. They really mark a new dawn in bladder-sparing approaches in bladder cancer in terms of integrating immune checkpoint blockade with radiation, or even without radiation in terms of trying to achieve bladder sparing. This is an approach that’s, of course, been used for decades. It is standard of care. There’s level one evidence for the approach, although it’s not practiced as frequently in some parts of the world as others. It could be that the integration of a new treatment modality into the bladder-sparing arena is a tipping point that is needed to really [motivate] the community to embrace this as a reasonable option for patients with bladder cancer.

Reference

Galsky MD, Daneshmand S, Chan KG, et al. Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in patients with muscle-invasive bladder cancer (MIBC): HCRN GU 16-257. J Clin Oncol. 2021;39(suppl 15):4503. doi:10.1200/JCO.2021.39.15_suppl.4503

Recent Videos
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content